Evidence map›Paper›PMID 40167642›Full record

ReviewVirchows Archiv : an international journal of pathology2025

Dermatofibrosarcoma protuberans with PDGFD rearrangements: a case series featuring a novel EMILIN1::PDGFD fusion and comprehensive literature review.

Sotiris Sotiriou, Kyriakos Chatzopoulos, Gregory W Charville, Gregory R Bean, Michael Michal, John M Gross, Julia A Bridge, Jerad M Gardner, Abbas Agaimy, Tony L Ng and 3 more

Abstract readReview
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. PDGF In Aesthetics: Hype Outpacing the Evidence?Journal of cosmetic dermatology · 2026
    Article
  4. Article
  5. Article
  6. Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma Harboring ZFP64::NCOA2/3 Fusions: A Series of 14 Cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sotiris SotiriouDepartment of Pathology, Aristotle University of Thessaloniki (AUTH), Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-6060-4995
Kyriakos ChatzopoulosDepartment of Pathology, Aristotle University of Thessaloniki (AUTH), Thessaloniki, Greece.
Gregory W CharvilleDepartment of Pathology, Stanford University, Stanford, CA, USA.
Gregory R BeanDepartment of Pathology, Stanford University, Stanford, CA, USA.
Michael MichalDepartment of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Plzen, Czech Republic.
John M GrossDivision of Surgical Pathology, Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA.
Julia A BridgeDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Jerad M GardnerDepartment of Dermatology, Geisinger Medical Center, Danville, PA, USA.ORCID http://orcid.org/0000-0001-7397-2159
Abbas AgaimyInstitute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany.
Tony L NgDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Jeffrey M CloutierDepartment of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Carla SaoudDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Ave, New York, NY, 10065, USA.
Konstantinos LinosDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Ave, New York, NY, 10065, USA. linosk@mskcc.org.ORCID http://orcid.org/0000-0001-9462-652X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA023108
6 · The paper itself

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a locally infiltrative mesenchymal neoplasm usually characterized by a COL1A1::PDGFB fusion. A minority of DFSPs have recently been shown to harbor alternative fusions, involving the PDGFD gene. The aim of this case series and literature review is to highlight the clinicopathologic and molecular features of PDGFD-rearranged DFSPs. Eighteen patients (twelve females and six males) with PDGFD-rearranged DFSPs were collected from the authors' institutional archives. Eight (44%) cases harbored a COL6A3::PDGFD fusion, five (28%) an EMILIN2::PDGFD fusion, and two (11%) an EMILIN1::PDGFD fusion. In three (17%) cases, the fusion partner was unknown. A literature review revealed 29 additional cases. Cumulatively, four alternative fusion genes have been detected: COL6A3::PDGFD (24/47, 51%), EMILIN2::PDGFD (12/47, 26%), EMILIN1::PDGFD (2/47, 4%), and TNC::PDGFD (1/47, 2%). In eight (17%) cases, the fusion partner was unknown. Most (20/24, 83%) COL6A3::PDGFD-fused DFSPs occurred in females with only four (17%) cases described in males. Additionally, half of them (12/24, 50%) developed in the breast/chest wall. EMILIN2::PDGFD-fused DFSPs often occurred in males, were located in the extremities (9/12, 75%), exhibited fibrosarcomatous transformation (9/12, 75%), were confined exclusively or primarily to the subcutis (10/12, 83%), and had a well-circumscribed contour (10/12, 83%). Specific molecular alterations in DFSPs correlate with certain clinicopathologic features. Notably, EMILIN2::PDGFD-fused DFSPs have a slight predilection for males, develop almost exclusively in the subcutis, tend to be well-circumscribed, and often exhibit fibrosarcomatous transformation, while COL6A3::PDGFD-fused DFSPs might have a predilection for the breast/chest wall of female patients. To the best of our knowledge, this is the first report of EMILIN1::PDGFD-fused DFSP.

Indexed as

Biomarkers, TumorDermatofibrosarcomaGene RearrangementLymphokinesMembrane GlycoproteinsOncogene Proteins, FusionSkin NeoplasmsAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedPlatelet-Derived Growth FactorBiomarkers, Tumorelastin microfibril interface located proteinLymphokinesMembrane GlycoproteinsOncogene Proteins, FusionPDGFD protein, humanPlatelet-Derived Growth FactorDermatofibrosarcoma protuberansDFSPEMILIN1PDGFD

Identifiers

PMID40167642
PMCPMC12439120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.